Microneedle–nanoparticle hybrid platforms for metabolic syndrome: advances in point-of-care diagnostics and transdermal therapeutics

Abstract Metabolic syndrome encompasses various conditions, including diabetes, obesity, and metabolic diseases. It is characterized by high blood sugar, abnormal cholesterol, and high blood pressure levels. Research has investigated combined methods using microneedles and nanoparticles for diagnosis and treatment to improve effectiveness while reducing harm to healthy tissues. This process allows potential improvements in diagnostic capabilities for detecting biomarkers associated with metabolic diseases. Using microneedles in conjunction with nanoparticles offers a promising avenue for advancements in metabolic disease management. With the potential for targeted and precise delivery of therapeutic agents, this integrated approach could revolutionize treatment strategies. Combining these technologies not only enhances the delivery and efficacy of existing treatments but also paves the way for new therapeutic modalities. The careful management and focused release of therapeutic agents made possible by this method could help create new treatment options that weren't possible before. As we learn more about this field, exploring the potential challenges and limitations associated with integrating microneedles and nanoparticles is crucial for metabolic diseases. Understanding these aspects is fundamental to guiding further advancement and ensuring the development of safe, effective, and patient-centric interventions.